Stress-Adaptive Responses Associated with High-Level Carbapenem Resistance in KPC-Producing
Affiliations
Carbapenem-resistant Enterobacteriaceae (CRE) organisms have emerged to become a major global public health threat among antimicrobial resistant bacterial human pathogens. Little is known about how CREs emerge. One characteristic phenotype of CREs is heteroresistance, which is clinically associated with treatment failure in patients given a carbapenem. Through whole-transcriptome analysis we tracked gene expression over time in two different strains (BR7, BR21) of heteroresistant KPC-producing first exposed to a bactericidal concentration of imipenem followed by growth in drug-free medium. In both strains, the immediate response was dominated by a shift in expression of genes involved in glycolysis toward those involved in catabolic pathways. This response was followed by global dampening of transcriptional changes involving protein translation, folding and transport, and decreased expression of genes encoding critical junctures of lipopolysaccharide biosynthesis. The emerged high-level carbapenem-resistant BR21 subpopulation had a prophage (1) disrupting associated with irreversible OmpK36 porin loss. On the other hand, OmpK36 loss in BR7 was reversible. The acquisition of high-level carbapenem resistance by the two heteroresistant strains was associated with distinct and shared stepwise transcriptional programs. Carbapenem heteroresistance may emerge from the most adaptive subpopulation among a population of cells undergoing a complex set of stress-adaptive responses.
Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance.
Su Y, Li Y, Yi Q, Xu Y, Sun T, Li Y J Fungi (Basel). 2025; 11(2).
PMID: 39997437 PMC: 11856953. DOI: 10.3390/jof11020143.
Kalu M, Tan K, Algorri M, Jorth P, Wong-Beringer A mSphere. 2022; 7(3):e0019022.
PMID: 35531657 PMC: 9241548. DOI: 10.1128/msphere.00190-22.
Pathway Driven Target Selection in : Insights Into Carbapenem Exposure.
Serral F, Pardo A, Sosa E, Palomino M, Nicolas M, Turjanski A Front Cell Infect Microbiol. 2022; 12:773405.
PMID: 35174104 PMC: 8841789. DOI: 10.3389/fcimb.2022.773405.
Mmatli M, Mbelle N, Maningi N, Osei Sekyere J mSystems. 2020; 5(6).
PMID: 33323413 PMC: 7771540. DOI: 10.1128/mSystems.00783-20.
Dai C, Wang Y, Sharma G, Shen J, Velkov T, Xiao X Antioxidants (Basel). 2020; 9(6).
PMID: 32526966 PMC: 7346118. DOI: 10.3390/antiox9060506.